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1. Introduction
The comprehension of the genetics or “OMICS” (referring to a field of study in biology 
ending in -omics, such as genomics, proteomics or metabolomics), serving as a determinant 
in the development of obesity, has led to the identifications of genes closely associated 
with obesity-related diseases or ailments. Understanding of the etiology of adipogenesis 
has been of interest to the global community, i.e., obesity genetics, as well as its regulatory 
mechanisms, with transcription factors (TFs) being instrumental in the worldwide epidem-
ics of overweight, with an increased risk for adiposity.
The identification of specific genes, sensitive to modulation by nutrients, as well as oxidative 
stress, inflammation mediators, endocrine factors/diseases, the turnover of lipids and carbo-
hydrates (i.e., glucose and fructose, in particular), and insulin resistance has become a major 
focal point of the current obesity epidemic in various developed countries. “Epigenetics” is 
now construed as an important mechanism for the development of obesity, which may ema-
nate from alterations in cellular chromatin structure without “touching” the DNA sequence 
itself, reaching from DNA methylation, histone modifications, and chromatin remodeling. 
The epigenetic modifications brought about by unhealthy “eating” affect nuclear and/or mito-
chondrial interplay, involving nuclear receptors like sirtuins, e.g., Sirt 1, serving as a single 
gene interacting with microRNAs, as well as transcription factors (TFs), e.g., p53, modulating 
cellular metabolism. These epigenetic players determine lipid turnover and energy expendi-
ture, thereby inducing senescence followed by incomplete DNA repair. Epigenetic modifica-
tions in various socials communities are at present believed to induce “nonalcoholic fatty 
liver disease” (NAFLD), associated with excess fat transfer to white adipose tissues (WATs), 
thus leading to obesity in developed countries. The overt failure of a series of antiobese drugs 
advocates the use of so-called nutrigenomic diets, enabling a reverse of the senescence, which 
ensures an early and successful nutritional intervention combatting NAFLD, preceding a 
reduction in the number of severe adiposity, worldwide.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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distribution, and reproduction in any medium, provided the original work is properly cited.
The enhancement in chronic diseases, such as obesity and diabetes (including early neurode-
generative diseases), is speculated to multiply by a factor of 5 by the year 2050, and will be 
linked to various organ diseases in the global population [1]. In overweight individuals, the 
increased adiposity is thought to be associated with epigenetic modifications, encompassing 
chromatin alterations induced by the environment and/or unhealthy diets. Genetic modifica-
tions inducing abnormal metabolic turnover in white adipose tissue (WAT) consolidate the 
defective nuclear mitochondrial interplay, leading to decrements in their energy expenditure.
Several hypotheses predicting the induction of obesity encompass the telomere-induction of 
cellular senescence associate a decline in telomeres with mitochondrial functioning [2, 3]. This 
phenomenon haunts humans in particular (in comparison to other mammals) and indicates 
that the human genes exhibit malfunctions in early childhood, like mitochondrial apopto-
sis associated with an enhanced probability of incurring nonalcoholic fatty hepatic disease 
(NAFLD), as well as degenerative, detrimental diseases [4, 5].
Furthermore, the theoretical aspects of age-related mutations and senescence [6, 7] have 
proven essential to describe the enhanced insulin resistance and the severity of weight gain 
and diabetes, which may be linked to xenobiotic ingestion in general [7, 8]. Adaptation model 
systems allude to theories of aging, postulating genetic alterations, like mutational patterns, 
which could be induced through excessive ingestion of dietary fats and sugars, which may 
lead to patterns of age-related mortality in general. Hereditary and/or evolutionary senes-
cence mechanisms encompass known genetic approaches, which may yield information 
related to age-specific patterns of segregating genetic traits in various populations. Modern 
genetic analyses, such as DNA or RNA microarray analyses, are now available to aid in pin-
pointing age-related changes in the genetic “interplay.” This has unraveled a solid identifi-
cation of novel, age-dependent genetic pathways of metabolism, which are associated with 
disturbances in the steady state of the appearance of new mutations within single genes 
involved in diseases like NAFLD, as well as obesity worldwide [8].
Various lifestyles in a global population could decrease, or event prevent, senescence as well 
as mutations, associated with the telomere shortening theory, thus improving in adaptation 
of man to his environment. A single gene, like Sirt1 (Sirtuin-1), being involved in longevity, 
may govern the expression of a plethora of genes being of relevance to the triggering of organ 
diseases in obesity and diabetes. Sirt1 may be of relevance to both (a) the telomere hypothesis 
[2] and (b) the mitochondrial theories of aging [3, 4].
In different, closed habitats, the phenotypical transformation of a “versatile,” i.e., beige adipo-
cyte phenotype, to the traditional white, triglyceride-storing, adipocytes, has been linked to a 
poor glucose homeostasis. This is now associated to diabetes and hepatic malfunctioning and a 
defective Sirt1, leading to insulin resistance. Sirt1-mediated malfunctioning with concomitant 
loss of appetite control and NAFLD development in experimental animals seems to involve 
other genes, such as the obese (ob), leptin, fat, and agouti genes [8]. Sirt1 dysregulation and 
insulin resistance are linked to diabetes and encompass genes like the “mature-onset diabetes 
of the young genes,” as well as others [9]. In obesity and diabetes, changes in Sirt1 expression 
is linked to the transcription factor p53, which enables the transformation the “normal” white 
adipose into an adipokine secreting tissue type, linked to NAFLD [6].
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2. Food restriction organ crosstalk in obese/diabetic “mice and men”
NAFLD may involve up to some 40% of individuals in the world population [7, 8]. Lipoprotein 
and glucose metabolism is disturbed in obese individuals [10] with increased lipid accumula-
tion and excess lipids stored in adipose tissue. In obese individuals, obesity manifests when 
the body mass index (BMI) reaches 30.0 kg/m2 [8]. However, nutrigenomic diets have shown 
good results in the treatment of NAFLD in both lean and obese individuals with BMI-values 
around 25 kg/m2) [11], resulting in a back-transformation of adipose tissue transformation (to 
a more white (WAT) phenotype), which is consequently linked to improved glucose turnover 
and less conspicuous NAFLD.
Abnormal lipid turnover in the liver may increase adiposity in obese individuals. Food restric-
tion studies have shown to normalize hepatic lipid metabolism, as well as adipose tissue type 
transformation associated with an altered immune response in obese individuals [12–16]. The 
observed gene-environment interactions pinpoints Sirt1 as the major defective gene involved 
in global obesity and NAFLD epidemics. Sirt1 dysregulation is therefore considered as the 
more prominent facilitators in the development of obesity, affecting the cell epigenetics (i.e., 
DNA sequence, methylation, and histone modifications). Like for the hepatic nucleoceptors 
[7], the adipose tissue counterparts are subjected to histone deacetylation by Sirt1, targeting 
transcription factors (TFs) like PGC-1α, p53, the pregnane X receptor (PXR), where the lat-
ter is known to bind vitamin K2 (i.e., MK-4 or MK-7) in order to modulate gene expression, 
adapting metabolic activity, insulin resistance, as well as the level of cellular and body inflam-
mation [7, 8, 10]. It is well known that Sirt1 is linked to appetite regulation through obesity-
related and diabetic genes [8], as well as the DNA repair system.
Transcriptional regulation of metabolic processes depends upon isoforms of PPARγ, interact-
ing with nuclear and mitochondrial genes via influence AMPK (5′-AMP activated protein 
kinase, AMPK) activation regulated by nutrient availability. Furthermore, Sirt1 deacetylation 
of Forkhead box protein O1 (FOXO1) controls apoptosis with regulation of xenobiotic metab-
olism and inflammation, as well as vitamin K2 (MK-4/MK-7). The specific effect of vitamin K2 
is described in detail in a separate book on vitamin K2, edited by Gordeladze, to be published 
in early 2017 by InTech Publishing Company. Suffice to mention here is that the involvement 
of Sirt1 in adipose tissue transformation is mediated by p53 transcriptional dysregulation, 
which causes repression of PPARγ and FOXO1, both being instrumental in the lipid metabo-
lism of adipocytes [17–20]. Finally, Sirt1/p53 interactions may modulate the adipocytes’ levels 
of adipocytokines, as well as immune responses, being important to maintain an abnormal 
adipose tissue-liver cross-talk leading to NAFLD in obesity [21–29].
In animal models of both obesity and diabetes, the disturbed adipogenesis being coupled 
to NAFLD [6, 30] is probably a result of the enhanced release of adipocytokines (i.e., apelin, 
leptin, adiponectin, and A-II =angiotensin-II), which is seen with the appearance of hepatic 
fibrogenesis, NAFLD, as well as neurodegenerative diseases [31, 32]. It is well known that 
food restriction, activating both Sirt1 and PGC-1α in tissues of transgenic (fat/NZO) mice, nor-
malized adipose tissue-liver cross-talk being associated with improved body weights, as well 
as hepatic lipid metabolism, reflecting the usefulness of this model system to adapt successful 
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treatments of NAFLD in obese patients. As expected, food restriction enhanced hepatic fatty 
acid oxidation in obese and/or diabetic mice; however, adipose tissue mass (body weights) 
was not altered in transgenic (i.e., ob, db, and Ay mice) expressing leptin resistance [30], 
which normally is linked to low activation levels of PGC1α by leptin.
The enhanced hepatic lipid turnover was not associated with improved adipocyte metabo-
lism in obese, diabetic, and/or agouti mice after prolonged food restriction. However, we 
have shown that treatment by vitamin K2 of both human stem cells and mouse preadipocytes, 
with gene-manipulated G
s
- and Gi2-alpha type G-proteins altered their phenotype from white (WAT) to “beige” (BAT-like), reducing the expression of white adipose tissue genes, while 
those of brown adipose tissue counterparts were enhanced [33].
The brain-liver-based metabolic pathway for the Alzheimer's disease-related peptide β-amyloid 
also involves Sirt1 [9]. In these patients, the adipose tissue loses its capability to process the 
β-amyloid in a normal fashion, now bringing about adipose tissue transformation [12, 31, 32], 
which leads to leptin resistance and NAFLD. Interestingly, food restriction fully restores the 
Sirt1/PGC-1α regulation of adipose tissue and liver lipid/β-amyloid turnover [32], thus involving 
the immune response with support for a mandatory role of the immune system in the progres-
sion of Alzheimer's disease in both the developing and developed world [32, 33]. Furthermore, 
aberrant posttranscriptional modulation of p53 determines liver affection and adipose tissue 
type transition in obesity.
Hence, abnormal gene regulation of the adipocytes’ metabolism seems to be closely linked to 
the hepatic lipid turnover, which in turn leads to failure to adapt to the environment, causing 
senescence and obesity. In obesity, the response to stress signals, which involve both Sirt1 
and the tumor suppressor protein p53, which are closely linked to insulin resistance [34] and 
metabolic processes, but also to cancer and DNA damage. Deficiency of p53 is linked to can-
cer and is interpreted as if a poor regulation of Sirt1 is involved, predisposing for cancer. 
An interest in the nutritional modulation of obesity, with or without concomitant diabetes, 
has increased due to the effects of feeding patterns on Sirt1 and p53, being involved in the 
reciprocal nuclear-mitochondrial interactions, emerging mutations, as well as apoptosis (cell 
death) and/or responses encompassing permanent cellular senescence [35–41]. Sirt1 and its 
posttranscriptional impact on p53 [42, 43] is heavily involved in the differentiation of adi-
pocytes, as well as lipid metabolism in general [44–48], with their implications for abnormal 
Sirt1 deacetylation of p53, linked to lipid metabolism with its characteristic transformation of 
adipocytes and ensuing liver disease. Interestingly, both Sirt1 and p53 knockout mice develop 
NAFLD [49–52], which alludes to a close connections between adipocyte phenotype “switch” 
involving Sirt 1 and/or p53 impact on mitochondrial functioning [53–56].
The leptin gene is but one of a plethora of genes determining food intake and body weight 
preservation where the transformation of adipose tissue is closely linked to p53-induced 
events, overriding the intrinsic control function of leptin or Sirt1 [57] in adipose tissue-
based metabolism of both glucose and lipids β-amyloid. Additionally, leptin from adipo-
cytes, with its augmented egress in obese subjects, is linked to inflammatory [58] or immune 
responses characterized by augmented circulatory levels of inflammatory derived cyto-
kines [12, 16, 20]. The condition known as “hyperleptinemia” is paralleled with enhanced 
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levels p53 and NAFLD, where there is a significant link between peripheral leptin levels, 
inflammation markers, and Kupffer cell activation [59]. Studies on food restriction in obese/
diabetic animals clearly demonstrated a lack of change in body weight, construed as abnor-
mally enhanced adipogenesis with concomitant and leptin disorders, which be relevant 
to obesity in humans in general [60]. Both in obese animals, as well as in human, a paral-
lel occurrence of NAFLD with hyperleptinemia are construed as being linked to a lack of 
hepatoprotective ability of the fat cells to secrete adiponectin [61–63], as well as diminished 
ability to prevent or dampen hepatic inflammation.
A plethora of p53-mediated interactions with the innate immune defense system [64–67] points 
to a function of p53 leading to immune homeostasis and/or inflammatory disease, which both 
are associated with hepatocyte senescence, lipid turnover, as well as a recruitment/attraction of 
natural killer (NK) cells [68, 69]. This persistence of “senescence” characterizing the cross-talk 
between white adipose tissue (WAT) and the liver does not facilitate the elimination/removal 
of the senescent cells; however, the p53-related promotion of adipose tissue adipogenesis with 
the development of NAFLD is allowed to take place. p53 is known to activate and suppress 
target genes like Sirt1, being associated with the innate immune response [70, 71], as well as 
and SREBP-1 (sterol regulatory element-binding protein-1) [45, 52], which serves as a key 
transcriptional regulator of the synthesis of lipids (triglycerides) in adipocytes. Sirt1, with its 
major role in lipid turnover in adipose tissue, is also metabolically “associated” to adiponectin 
release via the Sirt1/FOXO1 transcriptional complex [72, 73], known to maintain basic hepatic 
functions. The regulation of the liver and adipose tissue metabolism becomes evident as the 
p53 is released from the nucleus, implicating p53 itself and microRNA (miRNA) species in the 
aberrant regulation of fatty acid turnover in the mitochondria.
The impact of p53 on gene regulators encompasses miRNAs [74], where their function in the 
induction of obesity [75] hints to altered expression of multiple miRNA species in metabolic 
tissues [76, 77]. This also lends an important role to be played by an “abnormal” immune 
system [78–80]. Hitherto, the following findings pertaining to miRNAs involved are: MiR-103 
and -143 have been shown to be important in the “kick-off” and maintenance of adipogenesis 
[81], where miRNAs, e.g., miR-27 and miR-519d [82] serve as regulators of PPARγ [83], which 
accounts for the differentiation, as well as the overall number of fat cells. PPARγ is heavily 
expressed in adipocytes, i.e., especially in WAT, and plays a mandatory role in the Sirt1-medi-
ated transcriptional stimulation of adiponectin and leptin. The PPARα-mediated activation 
of Sirt1 yields an increase in lipid turnover through a general enhancement of β-oxidation. 
Furthermore, p53-associated miRNA dysregulation seems to be of importance, characterizing 
the aberrant metabolism of adipocyte-derived lipids, linked to the inactivation of nuclear-
mitochondrial crosstalk. Angiotensin II (AII, from the adipocytokine Apelin) [31] effectuates 
PPARγ-Sirt1 expression in the adipose tissue [32, 84, 85], playing a pivotal role in the produc-
tion and release of adiponectin [31, 32]. Furthermore, miRNA species such as miR-34a [86], 
miR-122, and miR-132 [87, 88], which directly obliterate the Sirt1-mediated biochemical pro-
cesses, bring about adiponectin release, to be construed as a poor activation of hepatic genes 
governing both glucose and lipid turnover [62]. Furthermore, the CCAAT/enhancer-binding 
protein alpha (C/EBPα) stimulates Sirt1 expression, which is coupled to adipogenesis through 
modulation of PPARγ [63], involving miR-34a.
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Underneath, a high-stringency emulation (using the Mir@nt@n algorithm), and based on the 
most recent scientific articles [86–90], the links between microRNA species and genes shown 
to be implicated in the development of the “fat liver syndrome” are shown in Figures 1 and 2, 
respectively.
Suffice to say, SIRT1, seems to be modulated by hsa-mir-30c, while, ABCA1-levels are deter-
mined by the integrated input of signals emanating from micro-RNA species like hsa-MiRs 144, 
148a, 145, and 33b. Future studies of these MiRs will show whether they might be targets or 
markers for gene manipulations normalizing liver metabolism, and thus combatting adiposity, 
in patients with aberrant lipid metabolism and/or adiposity.
Figure 1. High stringency emulation of gene-microRNA interactions, showing the impact of microRNA species on some 
“master” genes involved in the development of supersized adipocytes with the WAT (white adipocyte tissue-phenotype) 
alongside a fatty liver in patients developing nonalcoholic fatty liver disease (NAFLD).
Figure 2. High stringency emulation of gene-microRNA interactions, showing the impact of microRNA species on 
some “master” genes involved in the development of a fatty liver in patients developing nonalcoholic fatty liver disease 
(NAFLD).
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3. LPS modulation of Sirt1/p53 interactions is coupled to fat ingestion, 
dysfunction of the immune system, and metabolic liver disease
The immune-based hypotheses involve the aberrant regulation of Sirt1/p53 and a lack of 
adaptation to the environment, which implicates an abnormally functioning immune system 
in both the pathogenesis of insulin resistance and aging [85, 86]. Diets, which are high in fat 
and low in fibrous compounds, are linked to an enhancement of gut microbiota in the circula-
tion, with impact on immune functions, lowered insulin sensitivity, as well as energy homeo-
stasis in both animals and humans [77–83]. Noteworthy, animals fed a high fat/cholesterol 
diet demonstrated enhanced levels of bacterial endotoxins (known as lipopolysaccharides, 
LPS) with a parallel enhancement of inflammatory processes [64–66]. In this respect, both 
LPS and cytokines have been associated with enhanced hepatic sphingolipid synthesis with 
altered ceramide contents, which has been associated with peripheral insulin resistance. In 
obese mice, a change in inflammatory responsiveness was demonstrated subsequent to LPS 
administration [9, 10], followed by an alteration in intestinal microbiota and NAFLD, known 
to be closely correlated with systemic inflammation and the metabolic syndrome [11–16]. 
Hence, it was shown (verified) that the immune system is involved in the crosstalk between 
adipose tissue and liver, which inevitably implicates bacterial toxins in the pathogenesis and 
further development of NAFLD and obesity.
The LPSs are dimeric polysaccharide moieties linked to a lipid core, anchored within the cell 
membrane [18, 19], and have been shown to effect hepatic genomic stability [20] affecting 
reverse cholesterol transport (RCT) in macrophages by downregulation PPARγ [21–30]. LPSs 
have demonstrated to directly affect mitochondrial DNA synthesis linked to mitochondrial 
dysfunction [31]. LPSs are also involved in adipocyte-macrophage intercommunication, 
enhancing systemic inflammatory responses [32], being linked to DNA damage [33]. LPS 
and fat absorption have received increased interest, related to their effects on the Sirt1-medi-
ated modulation of hepatic cholesterol homeostasis, as well as their impact on β-amyloid 
metabolism [34].
LPS-binding proteins (LBPs) associate with LPS and alter inflammatory responses [35]. The 
LBPs, as well as leptin, are both upregulated in the obese, impinging on biological phenom-
ena, like the expression of leptin, appetite, and obesity-provoked inflammatory reactions 
[36–40]. LPS has, since long, been demonstrated to affect the efflux of cholesterol via the liver 
X Receptors (LXR) and the ATP-binding cassette transporter 1 (ABCA1) [41, 42] pathways, 
of which the latter is overriding the Sirt1-mediated impact on LXR-ABCA1 interactions. A 
lowering of the ingestion of fat [35] suppresses plasma LPS levels, and has therefore become 
a strong tool in the reduction of both the development and impact of metabolic diseases on 
health in general. LPS has been shown to modulate SREBP expression in macrophages, while 
also subduing liver PGC1α expression [29, 42, 43], and thus being associated with an abnor-
mal Sirt1-regulation of basal adipocyte cell functioning [27, 44]. The LPS-facilitated “block-
age” of the elimination of cholesterol from macrophages has been demonstrated to serve as 
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an important factor in the cholesterol-rich lipoprotein intercommunication network [45–47], 
thus impacting on LPS neutralization in metabolic diseases, with focus on diabetes [48–50].
LPS-induced production of interferon-gamma (IFγ) has been shown in both NK-cells and 
T- lymphocytes impacting genes encoding inflammatory cytokines, glucose metabolism, and 
macrophage-related modulation of genes in adipocytes [51, 52]. IFγ has also been shown to 
affect genes, like Sirt1 and p53 apoptosis coupled genes, whose role are being “dissociated” in 
dysfunctional stages of metabolism [45–53]. The impact of IFγ on chromatin modeling stim-
ulates macrophages, controlling gene transcription, thus regulating inflammatory cytokine 
production in activated macrophages [46, 47]. In this context, MiR-34a and other MiRs are 
involved in the modulation of the IFγ-mediated innate immune responses [48, 49]. However, 
one has discovered an inverse correlation between adiponectin and inflammatory cytokines, 
with adiponectin levels being associated with NK-cell activation [50–52].
The LPS-stimulated biological effect on p53-induced apoptosis in the liver [53, 54] sur-
passes the effect of Sirt1 as to the deacetylation of p53, reducing the hepatic lipid turn-
over. Hence, the p53-mediated downregulation of PXR activity [55, 56] is not dependent of 
the Sirt1/PXR-mediated reactions [57–60]. Therefore, the untoward p53/PXR interactions, 
which lead to NAFLD, are coupled to an altered expression of miRNA species related to 
the turnover of xenobiotics [61–63]. In this context, xenobiotic metabolism has been shown 
to be disturbed in obese individuals, which is associated with enhanced lipid synthesis 
[63], disturbed immune reactions [62], and marked apoptosis [64, 65]. The high levels of 
phthalates contained within alimentary like milk, butter, and meats are linked to the Sirt1/
p53 interactions [66–68], which couples the phthalates to NAFLD and adiposity in com-
munities worldwide [68].
Furthermore, the focus on α-synuclein and its impact on the immune system in the periph-
ery [69, 70] and CNS [71, 72] have emerged as knowledge about its regulatory impact on 
p53 transcriptional regulation of apoptosis has increased. Sirt1-mediated effects on hepatic 
α-synuclein and amyloid-β turnover are closely linked to LPS [72], metabolic diseases, as well 
as obesity, with observed impact on p53 transcriptional regulation by both α-synuclein and 
amyloid-β metabolism in the liver and brain [73–77].
4. Nutrigenomic diets block both hepatic and adipose tissue damage in 
obese individuals
A lack of effect of some anti-obese medications [78] in the treatment of obese patients has 
paved the way for nutrigenomic dieting, hopefully preventing the development of senes-
cence of various tissues being implicated in chronic disease states [1]. In obese patients, the 
success to be gained in early interventional treatments of NAFLD may depend upon individ-
uals [7, 8] having a BMI value of between 25 and 30 kg/m2, with a genuine reversal of adipose 
tissue transformation being coupled to solid improvements in glucose turnover immunoreg-
ulatory capacity, as well as NAFLD. In patients showing BMI values greater than 30 kg/m2, 
unhealthy diets inducing abnormal Sirt1/p53 interactions are often associated with changes 
in the levels of various microRNAs, inducing a chronic failure in the DNA repair system, 
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which accelerates hepatic senescence with ensuing adipose tissue inflammatory responses, as 
well as a dysfunctional lipid metabolism and aberrant energy expenditure.
Diets containing sufficient and appropriate protein “species,” carbohydrates, and low in 
fat upregulate both Sirt1 expression and activity in cells, leading to a positive effect on 
nuclear and mitochondria events, thus sustaining both lipid turnover and energy expendi-
ture. And, not to surprise anyone, food-restricted diets in young and genetically obese and 
diabetic mice, induce a reversal of hepatic lipid metabolism, involving Sirt1/p53 interac-
tions, which yields improved adipogenesis in man. Nutritional regulation may maintain 
p53 deacetylation by Sirt1, and thus sustain the “healthy” glucose homeostasis, which is 
paralleled with a swift energy disposal within adipose tissues. Additionally, ingested foods 
[32], able to block programmed cell death pathways, may be associated with expression of 
the Sirt1-gene, thus activating adipose tissues to synthesize and release factors (e.g., adipo-
nectin) [32], which will suppress the impact of inflammatory cytokines, in order to sustain 
“normal” liver function, thus blocking the induction of NAFLD in humans. Nutrigenomic 
diets, as for instance high fiber diets [79], will kick-start an “engineered” metabolism, allow-
ing for a joint physiological nuclear and mitochondrial interaction, which will stimulate the 
PPARγ-Sirt1 and Sirt1-PXR interactions coupled to both therapeutic nutrient and xenobiotic 
metabolism, that are associated with positive effects on p53 half-life and cell apoptosis [80].
Dieting and the immune system serve as synonymous with dietary fat and its composition 
being associated with NK cell activity and immune responses in the adipose tissue [81–83]. 
The suppression of Sirt1 expression by dietary fat is now associated with an abnormal p53 
mediated posttranscriptional regulation of NK cells [69, 83]. Furthermore, dietary fat may 
facilitate the absorption of LPS in rodents, but also man, by modulating the suppression of 
Sirt1 effects, while also promoting p53-mediated cell death. Hence, food restriction slows 
down LPS absorption, followed by an obliteration of LPS inhibition of cholesterol turnover in 
macrophages by the promotion of a reverse cholesterol transport.
A plethora of theories describing the process(es) of aging have been launched, however, 
the “immune theory” involves fat tissue transformation alongside an activation of its inher-
ent immune responses, encompassing macrophages and other immune cells. However, this 
adaptation model system is furthermore thought to include adipose tissues as the organs 
showing the highest susceptibility to apoptosis, with pathways of transformation largely 
linked to various mutations in a plethora of genes in different cells and tissues [6]. Hence, 
diets and our immune system are efficiently “cooperating” with our endogenous intesti-
nal microbial flora (i.e., Gram-negative bacteria) and environmental factors, impinging on 
dietary fatty acid compositions, which play a pivotal role in the immune homeostasis and 
reactivity of the liver. The Sirt1's involvement in the mitochondria theory of aging brings 
about a close link to mitochondrial dysfunction (i.e., Sirt1 downregulation), as well as an 
abnormal immune response [68, 84–86]. An essential requirement of some amino acids (e.g., 
leucine) [93] may sustain a nuclear and mitochondria p53-associated transport, along with 
an enhancement in the half-life of p53, as well as a blockage of immune dysfunction and 
development of NAFLD.
Nutrigenomic diets, like the low calorie diets, activating Sirt1, may lower plasma cholesterol 
concentrations [30], thus preventing hepatic p53-mediated apoptosis by xenobiotics and LPS. 
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A series of drugs, which inhibit Sirt1 [92] have been developed, which prevent leucine-medi-
ated activation of Sirt1 and xenobiotics (e.g., phthalates), modifying Sirt1 chromatin associa-
tion, with an ensuing induction of p53-mediated apoptotic responses [91–93] in both the liver 
and adipose tissue.
5. Summary
An increase in NAFLD/obesity in communities around the world, show that epigenetic modi-
fications are linked to malfunctioning of the gene Sirt1 along with p53 dysregulation of a 
defective adipose tissue-liver crosstalk. Healthy low calorie diets and/or an active lifestyle, 
maintaining adequate Sirt1/p53 interactions in obese individuals may decrease organ senes-
cence, as well as age-related mutations to occur. The ingestions healthy foods devoid of com-
ponents like sugars, fats, xenobiotics, and LPS may obliterate the induction of p53 cell-based 
apoptosis and Sirt1 suppression, but also enhance hepatocyte life span, thus preserving hepa-
tocyte nuclear and mitochondrial interactions. Metabolic stimulators of Sirt1 (i.e., leucine, 
polyphenols (e.g., resveratrol) and cathekins) may enhance hepatic xenobioitic turnover, as 
well as preventing mitochondrial death, linked to the dysregulation of NAFLD.
Nutritional diets, which promote the binding of Sirt1 to chromatin, thus preventing it from 
association, induced by various drug regimens, as well as unhealthy diets, will inevitably also 
prevent adipose tissue transformation, as well as activation of immune responses involving 
macrophages, NK cells, and lymphocytes that are associated with NAFLD, as well as other 
diseases seen in various habitats and communities.
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